novo nordisk glp-1 medications justifies reasoning behind failed Alzheimer's trials Novo Nordisk's oral GLP-1 drug

T., Jung, H

With growing interest in medications like semaglutide, patients are increasingly looking for ways to access these treatments in more convenient, tolerable formats

Have stable weight-related health conditions: If you have well-controlled high blood pressure, prediabetes, or high cholesterol, and your primary care doctor is aware you're pursuing GLP-1 treatment, the platform can coordinate care while your PCP continues managing your other health conditions

This study aimed to evaluate the effectiveness and safety of orforglipron, a nonpeptide, oral GLP-1 receptor agonist, for weight loss in adults with obesity